Recovery From Anesthesia After Robotic Assisted Radical Cystectomy
NCT ID: NCT03144453
Last Updated: 2019-01-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
50 participants
INTERVENTIONAL
2017-05-02
2019-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Optimal Relaxation Technique for Laparotomies With Rocuronium Infusion Followed by Sugammadex Reversal
NCT01539044
Deep Neuromuscular Block During General Anaesthesia in Robotic Surgery
NCT03420937
The Laparotomy Study
NCT02140593
Postoperative Urinary Retention in Patients After Noncardiac Surgery and Reversal of Neuromuscular Block
NCT05545280
Regional Anesthesia Versus General Anesthesia
NCT03830086
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sugammadex
The patients received sugammadex as neuromuscular blockade reversal
Sugammadex Injectable Product
Patients receive sugammadex at the end of the surgery
Standard
The patients received neostigmine + atropine as neuromuscular blockade reversal
Neostigmine, Atropine
Patients receive neostigmine+atropine at the end of the surgery
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sugammadex Injectable Product
Patients receive sugammadex at the end of the surgery
Neostigmine, Atropine
Patients receive neostigmine+atropine at the end of the surgery
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients underwent robotic assisted cystectomy
Exclusion Criteria
* BMI (body mass index) ≥ 30
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Regina Elena Cancer Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ester Forastiere
MD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ester Forastiere
Rome, RM, Italy
Regina Elena Cancer Institute
Rome, RM, Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CE/2288
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.